Scaling Lab Business to Clinical Evidence
BillionToOne at $153M/yr
The move into oncology turns a fast scaling lab business into a clinical evidence business. In prenatal screening, a doctor can order a blood test with familiar billing paths and limited product specific FDA friction. In oncology, each use case, picking a drug, tracking response, or watching for relapse, needs tighter validation, published data, and payer by payer coverage before volume can scale cleanly.
-
Prenatal testing is a simpler workflow. An OB draws one blood tube, sends it to a central lab, and gets a result in days. BillionToOne built UNITY around existing reimbursement mechanics and reached about 15% U.S. share in prenatal testing. Oncology adds many more stakeholders, including oncologists, pathology workflows, tumor profiling, and repeated testing over time.
-
Oncology reimbursement usually arrives indication by indication, not all at once. Natera and Guardant have spent years stacking Medicare coverage decisions across specific cancers and monitoring settings, which shows what expansion looks like in practice. The commercial moat comes from clinical studies and covered use cases, not just a more sensitive assay.
-
This is why lab capacity matters differently in cancer. A larger Austin facility is not just for more samples. It supports the quality systems, turnaround times, repeat testing cadence, and operational consistency needed when a blood result can influence therapy selection or show relapse months before imaging. That is the standard set by Guardant and Natera in liquid biopsy.
The next phase is less about proving that molecular counting works, and more about proving where it changes clinical decisions often enough to earn routine coverage. If BillionToOne keeps converting oncology studies into reimbursed use cases, it can evolve from a strong prenatal specialist into a broader precision diagnostics platform with much larger revenue per patient.